This week in drug discovery (9-13 October)  

News round-up for 9-13 October by DDW Digital Content Editor Diana Spencer.

The buzz with week has been around Phase I trials, with new therapies for lung cancer, geographic atrophy, Parkinson’s, sarcopenia and long Covid demonstrating positive early results or entering clinical trials for the first time.

The top stories:

Non-viral gene therapy shows early efficacy in lung cancer

Positive Phase I trial data indicates that Reqorsa (quaratusugene ozeplasmid) has shown early efficacy for the treatment of non-small cell lung cancer (NSCLC).

Advancing therapeutics to delay the onset of age-related diseases

Rejuvenate Biomed, a clinical-stage company advancing therapeutics to delay the onset of age-related diseases, has completed a six-week clinical proof-of-mechanism study with lead candidate RJx-01 for the treatment of sarcopenia.

Antibody treatment for geographic atrophy enters clinical trials

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA).

Allosteric therapy targets common genetic cause of Parkinson’s

Gain Therapeutics has initiated a Phase I clinical trial of GT-02287, the company’s lead drug candidate for the treatment of GBA1 Parkinson’s disease.

Could a common antiviral treat long Covid?

A UK-based study will investigate whether a common anti-viral medication could double up as a treatment for long Covid.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free